Title : Erythropoietin promoter polymorphism is associated with treatment efficacy and severe hematologic toxicity for platinum-based chemotherapy.

Pub. Date : 2021 Apr

PMID : 33461346






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Results: The TT genotype of EPO rs1617640 was significantly correlated with higher response rate to platinum-based treatment than the other genotypes (OR, 0.507; 95% CI: 0.305-0.842; P = 0.009), particularly in elderly patients (>55 years), male gender, smokers, IV stage, cisplatin-based chemotherapies and platinum-gemcitabine regimen subgroups. Cisplatin erythropoietin Homo sapiens
2 As for toxicity, EPO rs1617640 TT genotype demonstrated poorer tolerance to grade 3-4 hematologic toxicity (OR, 1.783; 95% CI: 1.098-2.898; P = 0.019), particularly in subgroups of elderly patients (>55 years), male gender, smokers, IIIA+IIIB stage and cisplatin-based chemotherapies. Cisplatin erythropoietin Homo sapiens